Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,116.00
Bid: 12,110.00
Ask: 12,112.00
Change: 66.00 (0.55%)
Spread: 2.00 (0.017%)
Open: 11,966.00
High: 12,124.00
Low: 11,966.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Stocks Rise On Expectation Of Dovish Draghi

Thu, 06th Jun 2019 12:15

LONDON (Alliance News) - Stocks in London were mixed Thursday at midday, with large- and mid-cap indices firmly in the green as investors anticipate a dovish outlook from Europe's central bank. In London, the FTSE 100 was up 51.64 points, or 0.7%, at 7,271.86 at midday. The FTSE 250 was up 25.33 points, or 0.1%, at 19,097.64. The AIM All-Share was down 1.2 points, or 0.1%, at 938.21.The Cboe UK 100 index was up 0.7% at 12,331.86. The Cboe UK 250 was up 0.2% at 17,156.27, and the Cboe UK Small Companies was marginally higher at 11,732.04.The pound was quoted at USD1.2697 at midday, down from USD1.2725 at the London equities close Wednesday.In Paris the CAC 40 and the DAX 30 in Frankfurt were both higher at midday, gaining 0.7% and 0.8%, respectively. "Stocks in Europe are higher as traders await the update from the European Central Bank. The eurozone is suffering from falling inflation, global trade tensions, and Italy and the EU are engaged in a spat over fiscal rules. The US Federal Reserve hinted they are willing to cut interest rates should they feel it is required, and now the pressure is on the ECB to go down the dovish route. The central bank is tipped to keep the refining rate and the deposit rate on hold at 0.0% and -0.4% respectively, but there is speculation we might hear more details about the planned targeted liquidity scheme which still begin in September," said CMC Market's David Madden.The ECB Governing Council is meeting in the Lithuanian capital of Vilnius, to announce its latest policy decision at 1245 BST. This will be followed by a press conference with ECB President Mario Draghi at 1330 BST.Analysts expect the ECB to maintain a dovish stance, while focus for investors will likely be on details of the central bank's latest round of targeted longer-term refinancing operations, as well as the latest round of economic projections.Madden added: "This year there has been a big shift in language, and in some cases actions, from central banks. The Fed have moved away from a hawkish view and they now open to potentially cutting rates. The Bank of Japan have used more dovish language recently, while rates have been lowered in Indian and Australia. The ECB are likely to move to a more dovish stance in order to play catch-up with its counterparts, and we might see stocks push even higher."The euro stood at USD1.1236 at midday, lower than USD1.1257 at the European equities close yesterday. Stocks in New York were set for a higher open on Thursday continuing the momentum seen earlier in the week following remarks by Fed Chair Powell that were interpreted by the market as indicating openness to a cut in US interest rates.The DJIA was called up 0.3%, the S&P 500 index up 0.3% and the Nasdaq Composite pointed up 0.4%.On the London Stock Exchange at midday, Rolls Royce was among the best performers in the FTSE 100, up 1.9% after the jet engine maker transferred around GBP4.1 billion of pension risk liabilities to Legal & General. Insurance firm L&G was up 1.1%. The deal covers the transfer of assets and liabilities relating to around 33,000 pensioners who are members of the Rolls-Royce UK Pension Fund, out of a total of 76,000 members. Aviva added 1.4% after the insurer said it will separate its UK business in two and cut 1,800 jobs over next three years as part of a plan to simplify the business, reduce costs and remove duplication.Aviva intends to separate its life and general insurance businesses in the UK, with the online direct business being integrated into UK general insurance unit. The company also intends to reduce costs by GBP300 million per annum by 2022 through lower central costs, savings in contractor and consultant spending, reduction in project expenditure, and other efficiencies. The cost savings are expected to lead to 1,800 job cuts over the next three years, out of a total workforce of around 30,000. Pharmaceutical firm AstraZeneca gained 1.3% at midday after it reported positive results from its trial of Calquence in patients with chronic lymphocytic leukaemia, a type of blood cancer. Astra said that the phase III ELEVATE-TN trial met its primary endpoint early. At the other end of the blue chip index, J Sainsbury, Kingfisher and Vodafone were the biggest losers, as all three stocks went ex-dividend Thursday. The supermarket was down 3.8%, the D&Y store chain down 3.6%, and the mobile operator down 3.4%. In the midcap FTSE 250 index, Entertainment One was the big winner, rising 16%. The film and television content developer surged after announcing that President & Chief Content Officer Mark Gordon will be staying at the company, contrary to reports in media industry magazine Variety. Entertainment One said veteran film and TV producer Gordon remains a part of the company both "now and into the future". Variety reported on Wednesday that Gordon was in talks to abandon the firm after conflict with Entertainment One's senior managers. Go-Ahead was up 9.3% after the public transport operator said it saw an improved trading performance since the start of 2019 as its revenue grew in regional bus and rail divisions. Go-Ahead's full-year expectations for its London & International bus division have been increased due to a "strong operating performance". Go-Ahead said it has seen "high levels of punctuality" across all of its divisions in the year to date.Stobart Group was up 5.9% after Jefferies initiated its coverage of the infrastructure and support services firm with a Buy rating.Mitchells & Butlers was up 4.1% after German investment bank Berenberg upgraded the pub and restaurant manager to Buy from Hold.Woodford Patient Capital Trust spent its third day languishing near the bottom of the FTSE 250, losing another 4.6%. Shares in the closed-end investment trust are down 25% so far in 2019.The UK financial regulator late Wednesday said it may open an investigation into LF Woodford Equity Income Fund if there are circumstances suggesting serious misconduct or non-compliance with its rules. On Monday, high profile fund manager Neil Woodford suspended withdrawals from the equity income fund as the fund's underperformance resulted in a significant outflow of investors. As at April 30, LF Woodford Equity Income Fund had GBP4.3 billion in assets. The equity income fund is managed by Woodford Investment Management, which also manages listed Woodford Patient Capital Trust. Trading in Woodford Patient Capital Trust remains unaffected by the suspension. Before the announcement by the authorities, FTSE 100-listed wealth manager St James's Place said Wednesday it has terminated its mandate with Woodford Investment Management. St James's Place was down 1.1% at midday on Thursday at midday. Still to come in the economics calendar Thursday, are US jobless claims, nonfarm productivity, and trade balance at 1330 BST.

More News
27 Mar 2024 09:19

AstraZeneca treatments become "first and only" to be approved in Japan

(Alliance News) - AstraZeneca PLC announced on Wednesday the approval of two of its treatments for use in Japan.

Read more
27 Mar 2024 09:03

LONDON MARKET OPEN: FTSE 100 slips as unease lingers before US data

(Alliance News) - Stock prices in London edged lower after the open on Wednesday, with some nervy trade ahead of a US inflation reading later in the week.

Read more
27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation reading later in the week.

Read more
26 Mar 2024 10:18

China to speed up 'new productive forces', vice president says

BEIJING, March 26 (Reuters) - China will accelerate the development of "new productive forces" and bolster stability and security for the global economy, Vice President Han Zheng told an investment forum in Beijing, as the world's no.2 economy seeks to reassure anxious foreign firms.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 09:04

LONDON MARKET OPEN: FTSE 100 treads water, FTSE 250 declines

(Alliance News) - The FTSE 100 in London traded flat early Monday, while the pound remained below the USD1.26 mark, as Bank of England Governor Andrew Bailey suggested rate cuts may happen soon.

Read more
25 Mar 2024 08:40

TOP NEWS: AstraZeneca wins US approval for rare nervous system disease

(Alliance News) - AstraZeneca PLC on Monday said its Ultomiris treatment has been approved by the US Food & Drug Administration as the first and only long-acting C5 complement inhibitor to treat neuromyelitis optica spectrum disorder in adults.

Read more
25 Mar 2024 07:59

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

Read more
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.